Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines.
COVID-19
case series
glomerulonephritis
macrohaematuria
vasculitis
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
07
12
2021
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Novel messenger RNA (mRNA)-based vaccines play an important role in current vaccination campaigns against SARS-CoV-2. They are highly efficacious and generally well tolerated. Vaccination in patients with immune-mediated kidney diseases is recommended. A number of cases with We collected 10 cases of macrohaematuria following mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at our tertiary care institution and referring centres. Additionally, we pooled all 25 published cases from the literature with ours to analyse their clinical characteristics. Most macrohaematuria episodes (72.2%) began within 2 days after vaccination, the majority after the second dose. In some individuals, repeated episodes occurred after subsequent doses of the same vaccine. A total of 65.7% of patients never had macrohaematuria before. A total of 45.7% were known to suffer from immunoglobulin A nephropathy (IgAN); the rest had no prior renal diagnosis. IgAN was the most frequent new diagnosis, but anti-neutrophil cytoplasmic antibody-associated vasculitis and anti-glomerular basement membrane disease were also identified. Acute kidney injury (AKI) occurred in 28.6% of patients, with an increase in serum creatinine not meeting Kidney Disease: Improving Global Outcomes AKI criteria in 28.6%. Treatment ranged from conservative management, renin-angiotensin-aldosterone system inhibitors, steroids and cyclophosphamide to plasmapheresis. While renal outcomes were mainly favourable in isolated IgAN, they were poor in patients with additional or isolated small vessel vasculitis. Awareness of gross haematuria after SARS-CoV-2 vaccination is important. Close follow-up and additional work up, particularly in individuals without known underlying kidney disease or worsening renal function, is essential. For patients with vaccine-associated macrohaematuria, an alternative vaccine class might be considered for subsequent vaccinations.
Sections du résumé
Background
UNASSIGNED
Novel messenger RNA (mRNA)-based vaccines play an important role in current vaccination campaigns against SARS-CoV-2. They are highly efficacious and generally well tolerated. Vaccination in patients with immune-mediated kidney diseases is recommended. A number of cases with
Methods
UNASSIGNED
We collected 10 cases of macrohaematuria following mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at our tertiary care institution and referring centres. Additionally, we pooled all 25 published cases from the literature with ours to analyse their clinical characteristics.
Results
UNASSIGNED
Most macrohaematuria episodes (72.2%) began within 2 days after vaccination, the majority after the second dose. In some individuals, repeated episodes occurred after subsequent doses of the same vaccine. A total of 65.7% of patients never had macrohaematuria before. A total of 45.7% were known to suffer from immunoglobulin A nephropathy (IgAN); the rest had no prior renal diagnosis. IgAN was the most frequent new diagnosis, but anti-neutrophil cytoplasmic antibody-associated vasculitis and anti-glomerular basement membrane disease were also identified. Acute kidney injury (AKI) occurred in 28.6% of patients, with an increase in serum creatinine not meeting Kidney Disease: Improving Global Outcomes AKI criteria in 28.6%. Treatment ranged from conservative management, renin-angiotensin-aldosterone system inhibitors, steroids and cyclophosphamide to plasmapheresis. While renal outcomes were mainly favourable in isolated IgAN, they were poor in patients with additional or isolated small vessel vasculitis.
Conclusion
UNASSIGNED
Awareness of gross haematuria after SARS-CoV-2 vaccination is important. Close follow-up and additional work up, particularly in individuals without known underlying kidney disease or worsening renal function, is essential. For patients with vaccine-associated macrohaematuria, an alternative vaccine class might be considered for subsequent vaccinations.
Identifiants
pubmed: 35498904
doi: 10.1093/ckj/sfab284
pii: sfab284
pmc: PMC9050541
doi:
Types de publication
Journal Article
Langues
eng
Pagination
961-973Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.
Références
Kidney Int. 2021 Aug;100(2):469-471
pubmed: 34033857
Kidney Int. 2021 Jun;99(6):1487
pubmed: 33771584
Kidney Int. 2021 Aug;100(2):466-468
pubmed: 34087252
Kidney Int. 2021 Jul;100(1):238
pubmed: 33932458
Kidney Int. 2021 Aug;100(2):473-474
pubmed: 34081948
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
PLoS One. 2021 Jun 16;16(6):e0249499
pubmed: 34133415
Blood. 2022 Mar 10;139(10):1564-1574
pubmed: 34587251
BMJ Case Rep. 2021 May 31;14(5):
pubmed: 34059544
IUBMB Life. 2017 May;69(5):297-304
pubmed: 28374903
Kidney Int. 2021 Aug;100(2):461-463
pubmed: 34000278
Kidney Med. 2021 Sep-Oct;3(5):860-863
pubmed: 34278290
Kidney Int. 2021 Aug;100(2):471-472
pubmed: 34119511
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):677-686
pubmed: 28159829
Lancet Rheumatol. 2021 Sep;3(9):e617
pubmed: 34250509
Kidney Int. 2021 Aug;100(2):474-476
pubmed: 34087251
J Am Soc Nephrol. 2020 Sep;31(9):1959-1968
pubmed: 32680910
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Am J Kidney Dis. 2021 Oct;78(4):477-480
pubmed: 34182049
JCI Insight. 2020 Jul 23;5(14):
pubmed: 32699192
Vaccines (Basel). 2021 Sep 25;9(10):
pubmed: 34696186
Kidney Int Rep. 2020 Jun 25;5(8):1149-1160
pubmed: 32775814
Kidney Int. 2021 Sep;100(3):706-707
pubmed: 34237323
Kidney Int. 2021 Oct;100(4):937-938
pubmed: 34416184
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
CEN Case Rep. 2022 May;11(2):166-170
pubmed: 34524643
Am J Kidney Dis. 2021 Oct;78(4):617
pubmed: 34273435
Kidney Int. 2021 Aug;100(2):459
pubmed: 34119512
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Kidney Int Rep. 2021 Sep;6(9):2523-2524
pubmed: 34337193
Kidney Int. 2021 Aug;100(2):464-465
pubmed: 33992674
Kidney Int Rep. 2021 Aug;6(8):2246-2247
pubmed: 34179593
Nephrol Dial Transplant. 2021 Mar 09;:
pubmed: 33693778
Kidney Int. 2021 Aug;100(2):458-459
pubmed: 34052236
Kidney Int. 2021 Aug;100(2):468-469
pubmed: 34146600
Kidney Int. 2021 Sep;100(3):705-706
pubmed: 34237324
Kidney Int Rep. 2021 Dec;6(12):2969-2978
pubmed: 34632166
Curr Rheumatol Rev. 2017;13(3):188-196
pubmed: 28521688
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Kidney Int. 2021 Oct;100(4):944-945
pubmed: 34352309
Kidney Int. 2021 Nov;100(5):959-965
pubmed: 34534551